Key Developments: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

3 Mar 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Pfizer Inc Forms Global Strategic Alliance with Merck KGaA
Monday, 17 Nov 2014 02:59am EST 

Pfizer Inc:Entered into an agreement with Merck KGaA, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody in development by Merck KGaA as a potential treatment for multiple types of cancer.Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of approved and investigational oncology therapies.  Full Article

Merck KGaA raises FY 2014 sales outlook and reiterates FY 2014 adjusted EBITDA outlook
Wednesday, 12 Nov 2014 07:00pm EST 

Merck KGaA:Raises sales guidance and reiterates forecast for EBITDA pre one-time items for full FY 2014.Assumes overall that sales will increase to approx. 11.0 to 11.2 billion euros; as of June 30, Merck had previously forecast sales of 10.9 to 11.1 billion euros.  Full Article

Merck KGaA to acquire Sigma-Aldrich
Monday, 22 Sep 2014 05:56am EDT 

Merck KGaA:Says together with Sigma-Aldrich Corporation (Sigma-Aldrich), have entered into definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (13.1 billion euros).Says will acquire all of outstanding shares of Sigma-Aldrich for $140 per share in cash.Says bridge financing has been secured for all-cash transaction.Says closing is expected mid-year 2015.  Full Article

Merck KGaA's EMD Serono and Sutro Biopharma to partner on development of Antibody Drug Conjugates
Wednesday, 17 Sep 2014 08:00am EDT 

Merck KGaA:EMD Serono, Inc., subsidiary of Merck KGaA, Darmstadt, Germany, and Sutro Biopharma, San Francisco, biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announces collaboration and license agreement to develop antibody drug conjugates (ADCs).ADCs are composed of an antibody linked to cytotoxic drug.The antibody is thought to specifically target and deliver the cytotoxic drug to cancer cells.Under terms of agreement, Sutro and EMD Serono will collaborate to discover and develop multiple ADCs utilizing Sutro's cell-free protein synthesis platforms, Xpress CF (tm) and Xpress CF+ (tm).Sutro will be responsible for delivering ADCs for Phase I clinical trials. EMD Serono will be responsible for clinical development and commercialization of any resulting products.  Full Article

Merck KGaA discontinues clinical development program of Tecemotide as Monotherapy in Stage III Non-Small Cell Lung Cancer
Friday, 12 Sep 2014 10:54am EDT 

Merck KGaA:Announces that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).Says its decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009.EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients with Stage III unresectable, locally advanced NSCLC who had received concurrent or sequential chemoradiotherapy (CRT).Results indicate that no effect has been observed for either the primary endpoint, overall survival (OS), or for any of the secondary endpoints (progression-free survival [PFS], time to progression [TTP] and time to treatment.  Full Article

Merck KGaA gives FY 2014 outlook, revenue and EPS outlook below analysts' estimates-Conference Call
Wednesday, 13 Aug 2014 08:00am EDT 

Merck KGaA:Expects FY 2014 sales corridor between 10.9 - 11.1 bln Euros.FY 2014 EBITDA pre expected to be in a range between 3.3 - 3.4 bln Euros.FY 2014 EPS pre, after the share split, between 4.50 - 4.75 Euros.All numbers are including the AZ acquisition.FY 2014 revenue 11.3 bln Euros, EBITDA of 3.3 bln Euros, EPS of 4.84 Euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA completes squeeze-out of AZ Electronic Materials
Wednesday, 2 Jul 2014 08:00pm EDT 

Merck KGaA:Announces that all remaining shares of AZ Electronic Materials (AZ) have been transferred to Merck KGaA on July 2.Holding 99.84 pct of the AZ shares already, Merck KGaA, had exercised its compulsory acquisition right (squeeze-out) on June 27.  Full Article

Merck KGaA and Mersana to develop next-generation antibody-drug conjugates
Tuesday, 24 Jun 2014 01:33am EDT 

Merck KGaA:Mersana and Merck KGaA to develop next-generation antibody-drug conjugates.Says to provide monoclonal antibodies to Mersana.Says to be responsible for clinical development, commercialization of products under exclusive license from Mersana.In addition to upfront payment, Mersana is eligible to receive milestones.  Full Article

Morphosys AG and Merck KGaA's Merck Serono enter strategic immuno-oncology collaboration
Thursday, 12 Jun 2014 01:36am EDT 

Morphosys AG and Merck:Sign agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.Under terms of agreement, MorphoSys and Merck Serono, biopharmaceutical division of Merck, will join forces to develop therapies that modulate immune system's natural ability to fight tumors.Say MorphoSys will apply its Ylanthia antibody phage library and technology platform to identify antibodies against targets of interest.Say Merck Serono with its portfolio and capabilities in field of immuno-oncology and clinical development will be fully responsible for execution of development from Phase 1 onwards.  Full Article

Merck KGaA announces FDA clearance for Auxogyn's Early Embryo Viability Assessment (Eeva) System
Tuesday, 10 Jun 2014 07:52am EDT 

Merck KGaA:Says that proprietary Early Embryo Viability Assessment (Eeva(R)) System of Merck Serono's strategic partner Auxogyn received clearance from the U.S. Food and Drug Administration (FDA) through its de novo classification process.Says regulatory pathway for select novel, low-to-moderate risk medical devices that are first-of-a-kind.Merck Serono is the exclusive commercial partner of Auxogyn, Inc., for the Eeva System in Europe and Canada.Eeva Test, used adjunctively to traditional morphology, is the first and only prognostic, non-invasive embryo test to receive clearance from the FDA.Says Eeva Test utilizes proprietary software that automatically analyzes embryo development against scientifically derived cell-division timing parameters captured through continual video imaging.This objective information provided to reproductive endocrinologists and embryologists helps to optimize treatment plans for their patients.  Full Article

Search Stocks